First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy

• Published in: Allergy (Copenhagen) Vol. 77; no. 10; pp. 3096 - 3107
• Main Authors: Nieto, Antonio, Mazón, Ángel, Nieto, María, Ibáñez, Ethel, Jang, Dah‐Tay, Calaforra, Susana, Alba, Pilar, Pérez‐Francés, Carmen, Llusar, Ruth, Montoro, Javier, Mateo, Antonio, Alamar, Remedios, El‐Qutob, David, Fernández, Javier, Moral, Luis, Toral, Teresa, Antón, Mónica, Andreu, Carmen, Ferrer, Ángel, Flores, Isabel‐María, Cerdá, Neus, Pozo, Sandra, Caballero, Raquel, Subiza, José Luis, Casanovas, Miguel
• Format: Journal Article
• Language: English
• Published: Denmark Blackwell Publishing Ltd 01.10.2022; John Wiley and Sons Inc
• Subjects: Allergens; allergoid; Allergoids; Animals; Antigens, Dermatophagoides; clinical trial; Dendritic cells; Dermatophagoides pteronyssinus; Double-Blind Method; Humans; Immunotherapy; Lymphocytes T; Mannan; Mannans; mmunotherapy; Oral administration; Original; ORIGINAL ARTICLES; Parasites; Placebos; polymerized; Provocation tests; Pyroglyphidae; Sublingual Immunotherapy - adverse effects; Treatment Outcome; Vaccines; clinical trial; i; polymerized; mannan; mmunotherapy; allergoid

Background Polymerized allergens conjugated to non‐oxidized mannan (PM‐allergoids) are novel vaccines targeting dendritic cells (DCs). Previous experimental data indicate that PM‐allergoids are readily taken up by DCs and induce Treg cells. This first‐in‐human study was aimed to evaluate safety and...